Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 1
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06790966Phase 3Active Not Recruiting

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Role: lead

NCT04260126Phase 2Completed

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

Role: lead

NCT02065973Phase 1Completed

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

Role: lead

All 3 trials loaded